Collectively, this work demonstratedthat the targeting of receptor tyrosine kinase signaling with LMW inhibitors ormonoclonal antibodies can improve the sensitivity of cancer cells to PPARγ ligand-mediatedgrowth inhibition. The gene discussed is PPARG; the disease is cancer.